Skip Nav Destination
            
    
            
 
    
    
        
            
                
                    
                        
                        
                            
                        
                    
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                     
    
                    
                    
        
        Targeting BCL-2 in B-cell lymphomas
        
        
            
        
    
        
    
            
                
            
    
    
    
        
        
     
    
                     
    
                    
                    
        
        A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
                    
                
            
    
    
    
        
        
     
    
                     
    
                    
                    
                
            
    
    
    
        
        
     
    
                     
    
                    
                    
                
            
    
    
    
        
        
     
    
                     
    
                    
        
        
     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
        
    
    
    
            
        
 
    
    
 
    
    
        
    
    
    
            
        
            
    
        
        
    
             
            
             
            
             
        
    
 
    
    
 
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
Table of Contents
INSIDE BLOOD COMMENTARIES
PERSPECTIVE
        
        Targeting BCL-2 in B-cell lymphomas
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
    
            BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
        
        A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Zhangyuan Kong,Ping Qin,Shan Xiao,Hai Zhou,Hong Li,Renchi Yang,Xiaofan Liu,Jianmin Luo,Zhichun Li,Guochao Ji,Zhongguang Cui,Yusheng Bai,Yuxia Wu,Linlin Shao,Jun Peng,Jun Ma,Ming Hou
            
        
    
            LYMPHOID NEOPLASIA
Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma
            Tomoko Narita,Takashi Ishida,Asahi Ito,Ayako Masaki,Shiori Kinoshita,Susumu Suzuki,Hisashi Takino,Takashi Yoshida,Masaki Ri,Shigeru Kusumoto,Hirokazu Komatsu,Kazunori Imada,Yuetsu Tanaka,Akifumi Takaori-Kondo,Hiroshi Inagaki,Arne Scholz,Philip Lienau,Taruho Kuroda,Ryuzo Ueda,Shinsuke Iida
            
        
    
            MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis
            Kellie R. Machlus,Stephen K. Wu,Prakrith Vijey,Thomas S. Soussou,Zhi-Jian Liu,Eran Shacham,T. J. Unger,Trinayan Kashyap,Boris Klebanov,Martha Sola-Visner,Marsha Crochiere,Joseph E. Italiano, Jr,Yosef Landesman
            
        
    
            RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSPLANTATION
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
            Lori Muffly,Marcelo C. Pasquini,Michael Martens,Ruta Brazauskas,Xiaochun Zhu,Kehinde Adekola,Mahmoud Aljurf,Karen K. Ballen,Ashish Bajel,Frederic Baron,Minoo Battiwalla,Amer Beitinjaneh,Jean-Yves Cahn,Mathew Carabasi,Yi-Bin Chen,Saurabh Chhabra,Stefan Ciurea,Edward Copelan,Anita D’Souza,John Edwards,James Foran,Cesar O. Freytes,Henry C. Fung,Robert Peter Gale,Sergio Giralt,Shahrukh K. Hashmi,Gerhard C. Hildebrandt,Vincent Ho,Ann Jakubowski,Hillard Lazarus,Marlise R. Luskin,Rodrigo Martino,Richard Maziarz,Philip McCarthy,Taiga Nishihori,Rebecca Olin,Richard F. Olsson,Attaphol Pawarode,Edward Peres,Andrew R. Rezvani,David Rizzieri,Bipin N. Savani,Harry C. Schouten,Mitchell Sabloff,Matthew Seftel,Sachiko Seo,Mohamed L. Sorror,Jeff Szer,Baldeep M. Wirk,William A. Wood,Andrew Artz
            
        
    
            LETTERS TO BLOOD
BLOOD WORK
- 
        
            Cover Image
        
        
Cover Image
            Platelets treated with selinexor retain cytoskeletal integrity (β-tubulin, green; F-actin, red), which suggests that selinexor-induced thrombocytopenia is not caused by aberrant platelet activation. See the article by Machlus et al on page 1132.
 - PDF Icon Front MatterFront Matter
 - PDF Icon Table of ContentsTable of Contents
 - PDF Icon Back MatterBack Matter
 - PDF Icon Editorial BoardEditorial Board
 
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals